Page last updated: 2024-10-20
pyrazinamide and Nutritional Disorders
pyrazinamide has been researched along with Nutritional Disorders in 1 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Pyrazinamide was used in addition to isoniazid and rifampicin in a significantly higher percentage of patients in the ATT-induced hepatitis group (70%) as compared with those in the control group (42%)." | 2.68 | Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. ( Arora, A; Garg, PK; Pande, JN; Singh, J; Tandon, RK; Thakur, VS, 1995) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Singh, J | 1 |
| Arora, A | 1 |
| Garg, PK | 1 |
| Thakur, VS | 1 |
| Pande, JN | 1 |
| Tandon, RK | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Antituberculosis Treatment Induced Hepatotoxicity[NCT00405301] | Phase 4 | 175 participants (Actual) | Interventional | 2006-12-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
1 trial available for pyrazinamide and Nutritional Disorders